European Approval Granted for Two Phase Ib Clinical Trials of Bionomics' BNC210
First trial will evaluate the potential for BNC210 to relieve panic attacks and reduce symptoms of anxiety
06-Oct-2010 -
Bionomics Limited announced approval from the French Medical Agency AFSSAPS (Agence Francaise de Securite Sanitaire des Produits de Sante) and the Ethics Committee of the Strasbourg Hospital, CPP (Comité de Protection des Personnes), to perform two advanced Phase I clinical trials with BNC210, ...
anxiety
anxiety disorder
central nervous system
+5